- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- ROUNDTABLE: Pharmacy’s future in sync with technology
PHILADELPHIA — Lannett has received approval from the Food and Drug Administration to market its version of an anti-obesity drug.
The FDA approved Lannett's abbreviated new drug application for diethylpropion hydrochloride extended-release tablets in the 75-mg strength. The company expects to begin shipping the product immediately.
“This approval fills out our portfolio of diethylpropion HCl products and adds to our growing portfolio of anti-obesity medications,” Lannett president and CEO Arthur Bedrosian said. “Since June 24, we have received five product approvals, the most in a four-month period in the company’s history, and a significant achievement for our team. Our pipeline remains deep, with a number of ANDAs currently pending at the FDA, several of which we expect to be approved over the next couple of quarters.”